A ligand from that library, FR159, was found to be able to inhibit E-cadherin-mediated cell-cell adhesion at low millimolar concentrations and better than ADH-1 (Exherin), a small cyclic peptide that had previously entered clinical trials in cancer patients (Perotti et al., 2009). This evidence concerns the gene CDH1 and cancer.